Immunovant Investor Relations Material

Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for patients with autoimmune diseases. Leveraging advanced anti-FcRn technology, Immunovant aims to create targeted therapies designed to address the complex and variable nature of autoimmune conditions. The company's approach is centered on improving the lives of patients by developing treatments that can potentially modify or halt the autoimmune response without compromising the immune system's ability to fight infections. Immunovant's research pipeline includes promising investigational products that embody the company's commitment to advancing the field of immunology and providing new options for individuals affected by autoimmune diseases. The company is headquartered in New York, NY, and its shares are listed on the Nasdaq.